MARKET INTRODUCTION
Erectile dysfunction (ED) is the incapacity to get and continue an erection firm during sexual intercourse. Erectile dysfunction can occur due to various problems, such as a combination of physical and psychological issues that result in erectile dysfunction. The drugs for ED produces an erection sufficient to start intercourse in men. The Food and Drug Administration (FDA) suggested and approved various prescription drugs that can be taken orally to treat ED.
MARKET DYNAMICS
Erectile dysfunction drugs market is anticipated to grow in the forecast period owing to driving factors such as increasing adoption of a sedentary lifestyle with the related stress, growing elderly population, and chronic diseases such as heart diseases, and diabetes. Moreover, advanced healthcare infrastructure and increasing attentiveness towards health in emerging economies are also offering opportunities in the market growth during the forecast period.
MARKET SCOPE
The "Global Erectile Dysfunction Drugs Market Analysis to 2031" is a specialized and in-depth study of the pharmaceuticals industry with a special focus on the global market trend analysis. The report aims to provide an overview of erectile dysfunction drugs market with detailed market segmentation by product, distribution channel, and geography. The global erectile dysfunction drugs market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading erectile dysfunction drugs market players and offers key trends and opportunities in the market.
MARKET SEGMENTATION
The global erectile dysfunction drugs market is segmented on the basis of product, distribution channel. Based on product, the market is segmented as Viagra (sildenafil citrate), Cialis (tadalafil), Levitra/ staxyn (Vardenafil), Stendra/Spedra (avanafil), Zydena (udenafil), Vitaros (alprostadil), and Others. Based on distribution channel, the market is segmented as hospital pharmacies, retail pharmacies, and online pharmacies.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global erectile dysfunction drugs market based on various segments. It also provides market size and forecast estimates from year 2021 to 2031 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The erectile dysfunction drugs market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting erectile dysfunction drugs market from both demand and supply side and further evaluates market dynamics affecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trends. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the erectile dysfunction drugs market in these regions.
MARKET PLAYERS
The report covers key developments in the erectile dysfunction drugs market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from erectile dysfunction drugs market are anticipated to lucrative growth opportunities in the future with the rising demand for erectile dysfunction drugs in the global market. Below mentioned is the list of few companies engaged in the Erectile dysfunction drugs market.
The report also includes the profiles of key erectile dysfunction drugs market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
- Ferring B.V.
- Bayer AG
- Eli Lilly And Company
- Teva Pharmaceutical Industries Ltd.
- Mylan N.V.
- Pfizer, Inc.
- Metuchen Pharmaceuticals LLC
- Vivus, Inc.
- Dong-A Pharmaceutical Co., Ltd.
- Glaxosmithkline Plc.
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.
Erectile Dysfunction Drugs Report Scope
Report Attribute | Details |
---|---|
Market size in 2023 | US$ XX Million |
Market Size by 2031 | US$ XX Million |
Global CAGR (2023 - 2031) | XX% |
Historical Data | 2021-2022 |
Forecast period | 2024-2031 |
Segments Covered |
By Product
|
Regions and Countries Covered | North America
|
Market leaders and key company profiles |
- Historical Analysis (2 Years), Base Year, Forecast (7 Years) with CAGR
- PEST and SWOT Analysis
- Market Size Value / Volume - Global, Regional, Country
- Industry and Competitive Landscape
- Excel Dataset
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Trends and growth analysis reports related to Life Sciences : READ MORE..
The List of Companies
1. Ferring B.V.
2. Bayer AG
3. Eli Lilly And Company
4. Teva Pharmaceutical Industries Ltd.
5. Mylan N.V.
6. Pfizer, Inc.
7. Metuchen Pharmaceuticals LLC
8. Vivus, Inc.
9. Dong-A Pharmaceutical Co., Ltd.
10. Glaxosmithkline Plc.
1. Ferring B.V.
2. Bayer AG
3. Eli Lilly And Company
4. Teva Pharmaceutical Industries Ltd.
5. Mylan N.V.
6. Pfizer, Inc.
7. Metuchen Pharmaceuticals LLC
8. Vivus, Inc.
9. Dong-A Pharmaceutical Co., Ltd.
10. Glaxosmithkline Plc.